LLY · News · 20260914N
Reimbursement and Pricing Policy - 340B
ELI LILLY & Co · 2026-09-14 · Importance 40 · Surprise 42 · In source text
Healthcare Dive reported that Lilly and Novo Nordisk have followed Johnson & Johnson in imposing stricter reporting requirements for providers seeking federal 340B discounts. The measures require claims-related information for drugs dispensed through the program, according to the report, to prevent duplicative discounts and alleged fraud. Providers argue that such requirements could restrict access to discounts that help hospitals and clinics afford high-priced medicines, creating reimbursement and compliance risk for Lilly.
Key facts
- Eli Lilly has taken actions similar to Johnson & Johnson and Novo Nordisk by imposing stricter reporting requirements tied to 340B discounts, requiring hospitals and clinics to submit claims data for each drug dispensed under the 340B program. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Eli Lilly has taken actions similar to Johnson & Johnson and Novo Nordisk by imposing stricter reporting requirements tied to 340B… |